AbCellera Biologics Inc. (ABCL)

AbCellera Announces Presentation of Phase 1/2 Data for ABCL635 at TMS 2026 Annual Meeting

AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026

AbCellera Biologics Inc. (NASDAQ:ABCL) Receives Consensus Rating of “Moderate Buy” from Analysts

ABCL Stock Surges 121% in 3 Months: Here's What You Need to Know

AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026

AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026

BlackRock Inc. Makes New Investment in AbCellera Biologics Inc. $ABCL

What'sGoing On With AbCellera Biologics Stock On Tuesday?

Are Biotech Stocks The 'Comeback Kid' Of 2026? I Say Yes

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

What's Going on With AbCellera Biologics Stock On Wednesday?

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Investors Buy Large Volume of AbCellera Biologics Call Options (NASDAQ:ABCL)

AbCellera Biologics Inc. (ABCL) Discusses Phase II Top Line Results for ABCL635 in Treatment of Moderate-to-Severe Hot Flashes Transcript

AbCellera Biologics Menopause Drug Data Shows 'New Efficacy Benchmark'

AbCellera Stock Jumps 33% on a Positive Menopause Trial

AbCellera's ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profi

AbCellera menopause drug cuts hot flashes in mid-stage trial, shares rise

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile